Biologics Market Global Briefing 2018

Biologics Market Global Briefing 2018

  • January 2018 •
  • 34 pages •
  • Report ID: 5057820 •
  • Format: PDF
The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

North America was the largest region in the biologics market in 2017, accounting for around 40% market share. This can be attributed to the high per capita healthcare expenditure in the region and the investment in novel treatments leading to the early adoption of new anti-inflammatory, anti-cancer and anti-viral biologics in the region.

Western Europe was the second largest region accounting for around 23% market share. Asia Pacific was the third largest region accounting for around 16% market share.

Demand For Biologics In The Treatment Of Complex Diseases - Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease that have limited treatment options. There has been a significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs.

The key biologics used for the treatment of Rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab ( Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.

We are very sorry, but an error occurred.
Please contact if the problem remains.